Biomark Diagnostics
Business Services · Canada · 1-10 Employees
View Company Info for Free
Overview
Headquarters
3851 Shell Rd 130, Richmond, British Col...Phone Number
(604) 370-0779Website
www.biomarkdiagnostics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Biomark Diagnostics
BioMark Diagnostics is a leader in early-stage cancer detection, utilizing advanced liquid biopsy technology to enhance cancer monitoring and screening solutions. Their innovative approach focuses on identifying biomarkers through metabolomics, which aids in the detection of hard-to-detect cancers. The company collaborates with oncologists and leverages artificial intelligence and machine learning to improve diagnostic accuracy and speed. BioMark's mission is to provide universal access to cutting-edge cancer diagnostics, ultimately aiming to increase survival rates through early detection.Explore more
Biomark Diagnostics Org Chart
BH
Software Developer
SC
Senior Quality Assurance Engineer
SL
Product Representative
TR
Artificial Intelligence & Big Data Senior Adv...
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Biomark Diagnostics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Biomark Diagnostics recently announced quarterly report
Biomark Diagnostics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Biomark Diagnostics had a recent Job posting/layoffs
Check if Biomark Diagnostics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Biomark Diagnostics launches new products
Website visits: Recent activity has been detected on your website
Check out if Biomark Diagnostics is spiking on competitors!
Funding: Get notified immidiatlly once Biomark Diagnostics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Biomark Diagnostics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Biomark Diagnostics
Compare insights from companies similar to Biomark Diagnostics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Biomark Diagnostics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Biomark Diagnostics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Biomark Diagnostics.
Biomark Diagnostics financials insights
Gather financial insights about Biomark Diagnostics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Grant
$139K
Biomark Diagnostics Tech Stack
A closer look at the technologies used by Biomark Diagnostics
See more technologies
Most Recent Scoops
Project
Product Management, Intellectual Property, Legal Affairs
Funding
Event
will be attending the 2022 BIO International Convention conference as an exhibitor. The event will occur from June 13 to June 16, 2022.
Event
Biomark Diagnostics News & Media
BioMark Announces the Final Closing of Oversubscribed Private Placement
Vancouver, British Columbia--(Newsfile Corp. - March 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"),...BioMark Announces Recent New Patent Granted in Canada to Support Its Liquid Biopsy Based Legacy Assay
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") a clinical and diagnostic laboratory developing a liquid biopsy molecular diagnostic tests with a focus on hard to detect and treat cancers, is pleased to announce today that the Canadian Intellectual Property Office (CIPO) has granted patent N° 2.906.236, on October 31, 2023. This patent entitled "Detection and Quantification of...BioMark Provides Second Quarter Operational Update and Announces Extension to Warrant Exercise Term
Vancouver, British Columbia--(Newsfile Corp. - November 28, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers today reports strong operational results from the second quarter ended September 30, 2023. The Company also announces that it intends to extend the warrant exercise term in a continuing effort to improve corporate value for its shareholders....BioMark Strengthens and Expands Its Strategic Advisory Team in Pursuit of Commercialization Initiatives
Vancouver, British Columbia--(Newsfile Corp. - November 14, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today the appointment of Dr. Randolph Ford to its Strategic Advisory team to enhance its data analytics and AI capabilities during the commercial acceleration of its early cancer detection technology. Mr. Rashid Ahmed Bux, CEO
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Biomark Diagnostics
Sign Up For FreeTo access detailed company insights
BioMark Diagnostics is a leader in early-stage cancer detection, utilizing advanced liquid biopsy technology to enhance cancer monitoring and screening solutions. Their innovative approach focuses on identifying biomarkers through metabolomics, which aids in the detection of hard-to-detect cancers. The company collaborates with oncologists and leve... Read More
